New therapies for relapsed or refractory aggressive B-cell lymphoma increase survival: Analysis from the RELINF registry of the GELTAMO group.
Bastos-Oreiro M, Abrisqueta P, Gutierrez A, Jiménez Ubieto A, Poza M, Fernanez-Caldas P, LLacer MJ, Gonzalez de Villambrosia S, Córdoba R, López A, Ceballos E, Navarro B, Muntañola A, Donato E, Diez-Baeza E, Escoda L, Luzardo H, Peñarrubia MJ, García Belmonte D, Pardal E, Lozada C, Martín García-Sancho A.
Bastos-Oreiro M, et al. Among authors: abrisqueta p.
Hemasphere. 2024 Apr 22;8(4):e70. doi: 10.1002/hem3.70. eCollection 2024 Apr.
Hemasphere. 2024.
PMID: 38650598
Free PMC article.
No abstract available.